Using molecular profiles of human health and disease to develop diagnostics and therapeutics

Global Genomics Group (G3T) employs a groundbreaking approach to drug discovery and development by leveraging human genomics to identify and validate potential drug targets. Their methodology begins with extensive genomic sequencing of the human genome across thousands of individuals, allowing them to connect specific genetic targets to various diseases. This process is enhanced by measuring a wide array of intermediate biomarkers, which facilitates the identification of drug targets for diseases with available phenotype information. G3T's platform is designed to de-risk the drug development process by establishing evidence of human efficacy prior to in-vitro studies, thereby increasing the likelihood of successful clinical outcomes.

The company’s innovative pipeline includes a novel drug candidate targeting non-alcoholic steatohepatitis (NASH) and cardiovascular disease, which operates through a unique biological mechanism distinct from traditional cholesterol-lowering drugs. Additionally, G3T has developed knowPLAQUE, a patented blood test that can detect harmful plaques in the heart without the use of radiation, providing a non-invasive diagnostic tool for coronary artery disease. G3T's approach is underpinned by a comprehensive understanding of the human "panome," which encompasses all molecular components in the body, and is structured around three pillars: deep quantitative phenotyping, panomic molecular profiling, and deep learning to generate insights from extensive biological data.

United States

G3 leverages molecular profiles of human health and disease to develop life changing diagnostics and therapeutics.

Global Genomics Group

Company Details